Clinical Trial Update: The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I [NA]

View source ↗

Summary

The clinical trial evaluating the Selective Cytopheretic Device (SCD) for acute kidney injury and hepatorenal syndrome Type I has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatorenal Syndrome
• Kidney Injury

Drugs mentioned

• Selective Cytopheretic Device (SCD)

Snippet

Sponsor: Lenar Yessayan | Conditions: Acute Kidney Injury, Hepatorenal Syndrome | NA | Status: SUSPENDED